Kingston

Researchers are investigating the best way to use Selective Laser Trabeculoplasty (SLT) therapy for people with glaucoma or ocular hypertension. The study aims to find out if performing SLT at a low energy level is as effective as using the standard energy level. It also evaluates whether repeating low energy SLT once a year can better prevent or delay the need for daily eye drop medications compared to waiting until the effects of the initial SLT wear off before repeating the treatment. Participants will receive SLT treatments at either low energy or standard energy levels. The study compares these two approaches to see which is more effective over time. Some participants will have their low energy SLT repeated annually to assess if this schedule helps in managing their eye condition better than waiting for the treatment effects to diminish before repeating SLT. During the study, participants will be monitored for up to 48 months to track their survival without requiring daily eye drops, with primary outcome measures at 12 and 48 months. Researchers will check eye pressure and overall eye health regularly, ensuring safety and effectiveness of the treatments. Participants need to attend scheduled visits and follow study procedures throughout the study duration, which may include periodic eye exams and assessments.

Researchers are evaluating patient and surgeon satisfaction, bruising, eyelid symmetry, wound closure success, and case time in adults undergoing blepharoplasty with the Ziplyft17 device. Ziplyft17 is a novel surgical tool designed to remove excess eyelid skin and is classified as a Class 1, 510(k) Exempt device. The study focuses on measuring outcomes related to facial appearance, eye area, and surgical efficiency over a 3-month period. Participants will undergo the blepharoplasty procedure using Ziplyft17. The study tracks the success of tissue adhesive used for wound closure and monitors postoperative bruising and eyelid symmetry. Both patient satisfaction with facial appearance and surgeon satisfaction and efficiency will be assessed from the time of enrollment until the last visit, which occurs 3 months after the procedure. During the study, participants will be evaluated at enrollment and followed up until 3 months post-procedure. Assessments include patient-reported satisfaction, surgeon feedback, measurements of eyelid symmetry, bruising, and the effectiveness of wound closure. The study also measures improvements in "eye age" and case time to evaluate the overall surgical experience and outcomes.

Researchers are evaluating surgical and minimally invasive treatments for lumbar spinal stenosis (LSS) by comparing Medicare patients who received the MILD procedure against those who had interspinous process decompression (IPD). The study focuses on outcomes such as the rate of harms related to the initial procedure and the frequency of additional surgical or minimally invasive interventions within 24 months after treatment. Enrollment includes patients treated from January 1, 2017, onward, with continuation until the sponsor decides to stop. The MILD procedure involves percutaneous image-guided lumbar decompression, performed under fluoroscopy through a dorsal approach to partially remove tissue and bone at the affected spinal level. The control group receives the IPD procedure for LSS. Both groups are monitored for a 24-month period post-index procedure using Medicare claims data to track reoperations and any harms. Participants contribute data through Medicare claims without needing prior enrollment or consent, as the study is exempt from IRB oversight. Researchers collect and analyze information on procedure-related harms and subsequent interventions over two years. This approach allows evaluation of long-term safety and effectiveness outcomes for patients treated with either MILD or IPD.

This research study focuses on people who have dry eye and find it difficult to wear contact lenses comfortably for long periods. The study aims to evaluate whether the regular use of Lacrifill, a treatment designed to improve contact lens tolerance, can reduce signs and symptoms of dry eye and help people wear their contacts longer without discomfort over a 2-3 month period. This is a Phase 4 clinical trial assessing Lacrifill's safety and ease of use for this purpose. Participants will use Lacrifill, a cross-linked hyaluronic acid derivative that temporarily blocks tear drainage to keep the eyes bathed in natural tears. The study involves a single treatment group where all participants will receive Lacrifill. The treatment is intended to be used regularly during the study period lasting 2-3 months. During the study, participants will be monitored for dry eye signs, symptoms, and their ability to tolerate contact lenses. Researchers will assess these outcomes over the 2-3 month timeframe to determine the treatment's impact. The study involves regular evaluations to track changes in eye condition and contact lens comfort throughout the participation period.